Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the french named patient program

Clinical Infectious Diseases

Volumn 60, Issue 10, 2015, Pages 1521-1527

  Descamps, Diane ^a,b,c   Peytavin, Gilles ^a,b,c   Visseaux, Benoit ^a,b,c   Tubiana, Roland ^d,e   Damond, Florence ^a,b,c   Campa, Pauline ^f   Charpentier, Charlotte ^a,b,c   Khuong Josses, Marie Aude ^g   Duvivier, Claudine ^h,i   Karmochkine, Marina ^j   Lukiana, Tuna ^k   Matheron, Sophie ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c BICHAT HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g DELAFONTAINE HOSPITAL   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ IHU Imagine   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k VIIV HEALTHCARE   (United States)

more..

Author keywords

dolutegravir; drug resistance mutations; HIV 2; integrase

Indexed keywords

CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; AGED; BLOOD; CHEMISTRY; DRUG EFFECTS; FRANCE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 2; ISOLATION AND PURIFICATION; MIDDLE AGED; PLASMA; PROCEDURES; SALVAGE THERAPY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MALE; MIDDLE AGED; PLASMA; RNA, VIRAL; SALVAGE THERAPY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84929179270     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ124     Document Type: Article

References (43)

1. Gottlieb GS, Hawes SE, Wong KG, et al. HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal. AIDS Res Hum Retroviruses 2008; 24:857-64.
2. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 2007; 21:2351-3.
3. Gurjar RS, Ravi V, Desai A. Molecular epidemiology of HIV type 2 infections in South India. AIDS Res Hum Retroviruses 2009; 25:363-72.
4. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11:934-6.
5. Nam JG, Kim GJ, Baek JY, et al. Molecular investigation of human immunodeficiency virus type 2 subtype a cases in South Korea. J Clin Microbiol 2006; 44:1543-6.
6. Valadas E, Franca L, Sousa S, Antunes F. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009; 48:1166-7.
7. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13:587-96.
8. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
9. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
10. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008; 47:9345-54.
11. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-74.
12. Charpentier C, Larrouy L, Collin G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 2010; 24:2753-5.
13. Koh Y, Matreyek KA, Engelman A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J Virol 2011; 85:3677-82.
14. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-20.
15. Smith RA, Raugi DN, Kiviat NB, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 2011; 25:2235-41.
16. Smith RA, Raugi DN, Pan C, et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One 2012; 7: e45372.
17. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52:981-94.
18. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, noninferiority SAILING study. Lancet 2013; 382:700-8.
19. Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012; 25:677-86.
20. Avettand-Fenoel V, Damond F, Gueudin M, et al. New sensitive onestep real-time duplex PCR method for group A and B HIV-2 RNA load. J Clin Microbiol 2014; 52:3017-22.
21. Charpentier C, Eholie S, Anglaret X, et al. Genotypic resistance profiles of HIV-2-treated patients in West Africa. AIDS 2014; 28:1161-9.
22. Visseaux B, Hurtado-Nedelec M, Charpentier C, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis 2012; 205:111-20.
23. Damond F,Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004; 20:666-72.
24. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197-201.
25. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21:1095-104.
26. Rapport 2013 sur la prise en charge médicale des personnes vivant avec le VIH.: sous la direction du Professeur Philippe Morlat, 2013. Available at: http://www.sante.gouv.fr/IMG/pdf/Rapport-Morlat-2013-Mise-en-ligne.pdf. Accessed 1 March 2015.
27. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-31.
28. Song I, Chen S, Piscitelli S, Min S. Pharmacokinetics (PK) and PKpharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naive subjects [abstract A-1573]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 10-13 September 2013, Denver, CO.
29. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviralexperienced patients with raltegravir-And/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210:354-62.
30. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 2013; 207:740-8.
31. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-9.
32. Charpentier C, Laureillard D, Sodqi M, et al. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-Associated mutations (TAMs) in HIV-infected patients. J Clin Virol 2008; 43:212-5.
33. Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. AIDS 2004; 18:1076-8.
34. Stegmann S, Manea ME, Charpentier C, et al. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol 2010; 47:79-81.
35. Delory T, Papot E, Rioux C, et al. Association de Foscarnet et Dolutegravir dans le traitement des infections VIH avancées: une série de 5 cas [abstract 20]. In: Journées nationales d'Infectiologie, Bordeaux, France, 2014.
36. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-21.
37. Vavro C, Dudas K, Hasan S, Huang J, Yeo J, Underwood M. Dolutegravir treatment of HIV subjects with raltegravir resistance: integrase resistance evolution in cohort II of the VIKING study [abstract 5]. In: International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Sitges, Spain, 2012.
38. Smith RA, Raugi D, Pan C, et al. Raltegravir-Associated mutations in HIV-2 confer cross-resistance to dolutegravir in vitro [abstract 574]. In: Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014.
39. Huang W, Frantzell A, Whitcomb JM, et al. Impact of raltegravir/elvitegravir selected mutations on dolutegravir cross-resistance [abstract 595]. In: Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014.
40. HuangW, Frantzell A, Whitcomb JM, et al. Characterization of dolutegravir cross resistance among HIV-1 containing raltegravir/elvitegravir selected resistance mutations. Antivir Ther 2014; 19(Suppl 1):A151 [abstract 105]. In: International Workshop on Antiviral Drug Resistance, Germany, 2014.
41. Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-Associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013; 57:2654-63.
42. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696-705.
43. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25:1737-45.